BioSpace News Archive

Eargo, Inc., a medical device company on a mission to improve the quality of life of people with hearing loss, reported its financial results for the second quarter ended June 30, 2021.

AVITA Medical, Inc., a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced it plans to release its fiscal fourth quarter 2021 financial results after the market closes on Thursday, August 26, 2021.

Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, today reported financial results for the second quarter and first six months of 2021 and provided business highlights.

Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.

Kronos Bio, Inc., a company dedicated to transforming the lives of those affected by cancer, reported recent business progress and second quarter financial results.

Nkarta, Inc., a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, reported financial results for the second quarter ended June 30, 2021.

Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it has signed an exclusive distribution agreement with Enlight Medical, a leading company in the development, production and distribution of innovative medical diagnostics and therapeutic devices in China.

Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced financial results for the three months ended June 30, 2021 and provided a business update.

Eledon Pharmaceuticals, Inc., (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), today reported its second quarter 2021 operating and financial results.

Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), today reported financial results and operating highlights for the second quarter and six months ended June 30, 2021.